Aripiprazole Tablet
Product Images NDC 70518-2150

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole 5mg 70518 2150 02

Label for Aripiprazole 5 mg oral tablet by RemedyRepack Inc. The label indicates a quantity of 30 tablets with a pink rectangle background behind the strength. Manufacturer is Alembic Pharma, Bridgewater, NJ. Storage instructions specify keeping medication out of reach of children and storing between 20-25°C with permitted excursions.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

A chart depicting fold change and 90% confidence intervals in pharmacokinetic parameters (AUC and Cmax) relative to a reference without interacting drugs. The y-axis lists various interacting drugs and enzymes such as CYP2D6, CYP2C9, S-warfarin, and others, with corresponding changes plotted as squares with error bars along the x-axis representing fold change values from about 0.5 to 3.0.*

FDA Label Image

Aripiprazole Fig 6

A Kaplan-Meier survival curve chart showing the proportion with relapse over 182 days from randomization for Aripiprazole versus placebo groups. The chart includes the number of subjects at risk at different time points for both groups, with Aripiprazole depicted as a solid line and placebo as a dashed line.*

FDA Label Image

Aripiprazole Fig 9

Line graph titled 'Change in YGTSS Total TIC Score From Baseline' showing least-squares mean change in total TIC score over 8 weeks of treatment. The graph compares three groups: Aripiprazole Low dose, Aripiprazole High dose, and Placebo. Both Aripiprazole groups show a greater decrease in TIC score over time compared to Placebo.*

FDA Label Image

Figure 7 (Aripiprazole Figur7)

A Kaplan-Meier plot comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1. The chart includes a table of the number of subjects at risk at various time points for each group.*

FDA Label Image

Aripiprazole Figure1

A horizontal error bar chart showing the effect of different drugs on aripiprazole pharmacokinetics. The x-axis represents the fold change relative to a reference without interacting drugs, ranging from 0.5 to 3. The y-axis lists drug categories including CYP3A4 inhibitor (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam), showing their impact on aripiprazole AUC and Cmax with 90% confidence intervals.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A pharmacokinetic bar graph showing the effect of various drugs on Aripiprazole's dehydro-aripiprazole AUC and Cmax. The chart lists CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs with fold change and 90% confidence intervals relative to the reference without interacting drugs.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

Pharmacokinetic (PK) chart showing Aripiprazole fold change with 90% confidence intervals for area under curve (AUC) and maximum concentration (Cmax) comparing special populations including CYP2D6 metabolizer status, gender, age groups, hepatic impairment, and severe renal impairment relative to reference values.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A pharmacokinetic chart showing fold change and 90% confidence intervals for Dehydro-Aripiprazole levels relative to reference values. Variables compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with measurements for AUC and Cmax plotted on a horizontal axis representing change relative to reference.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, showing its molecular framework including two chlorine atoms on a benzene ring and a complex fused ring system connected via a nitrogen-containing linker chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.